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Abstract
Background and aim: Recent studies have proposed that commensal bacteria might be involved in the
development and progression of gastrointestinal disorders such as colorectal cancer (CRC). Therefore, in this study,
the relative abundance of Fusobacterium nucleatum, Bacteroides fragilis, Streptococcus bovis/gallolyticus, and
Enteropathogenic Escherichia coli (EPEC) in CRC tissues, and their association with clinicopathologic characteristics of
CRC was investigated in Iranian patients. Moreover, the role of these bacteria in the CRC-associated mutations
including PIK3CA, KRAS, and BRAF was studied.
Method: To these ends, the noted bacteria were quantified in paired tumors and normal tissue specimens of 30
CRC patients, by TaqMan quantitative Real-Time Polymerase Chain Reaction (qPCR). Next, possible correlations
between clinicopathologic factors and mutations in PIK3CA, KRAS, and BRAF genes were analyzed.
Results: In studied samples, B. fragilis was the most abundant bacteria that was detected in 66 and 60% of paired tumor
and normal samples, respectively. Furthermore, 15% of the B. fragilis-positive patients were infected with Enterotoxigenic
B. fragilis (ETBF) in both adenocarcinoma and matched adjacent normal samples. F. nucleatum was also identified in 23%
of tumors and 13% of adjacent normal tissue samples. Moreover, the relative abundance of these bacteria determined by
2-ΔCT was significantly higher in CRC samples than in adjacent normal mucosa (p < 0.05). On the other hand, our findings
indicated that S. gallolyticus and EPEC, compared to adjacent normal mucosa, were not prevalent in CRC tissues. Finally,
our results revealed a correlation between F. nucleatum-positive patients and the KRAS mutation (p = 0.02), while analyses
did not show any association between bacteria and mutation in PIK3CA and BRAF genes.
Conclusion: The present study is the first report on the analysis of different bacteria in CRC tissue samples of Iranian
patients. Our findings revealed that F. nucleatum and B. fragilis might be linked to CRC. However, any link between gut
microbiome dysbiosis and CRC remains unknown.
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Introduction
Colorectal cancer (CRC) is identified as one of the lead-
ing causes of morbidity and mortality around the world.
It is known as the third most prevalent cancer in Iran
and its mortality rate has been growing in recent years
[1–3]. In the 1996–2000 period, the incidence rate of
CRC was 7–8 per 100,000 for both males and females in
Iran [4], while this rate increased to 11.8 and 16.5 (per
100,000) for females and males, respectively, in 2014 [5].
The World Health Organization (WHO) reported in
2014 that the CRC incidence rate, particularly among
men, had been rapidly increased in the past decades in
Eastern Europe and Asia, including Iran [6].
Hereditary forms, such as familial adenomatous
polyposis and hereditary non-polyposis colon cancers,
constitute less than 5% of CRCs, while the majority are
sporadic cases caused by factors such as environmental
exposures and lifestyle. CRC is a multistep carcinogenic
disease and recent studies have reported that the gut
microbiome may have a key role in colorectal tumori-
genesis [2, 7]. Furthermore, CRC is related to oxidative
processes and chronic inflammation which may induce
malignant cell transformation and trigger carcinogenic
processes like angiogenesis and proliferation [8].
Besides, a high prevalence of infectious agents such as
Fusobacterium nucleatum, Bacteroides fragilis, Strepto-
coccus gallolyticus, and Enteropathogenic Escherichia
coli (EPEC), in tissue or fecal samples of CRC patients
has been reported [9–12]. Based on different observa-
tions, bacterial-driven oncogenic mechanisms such as B
catenin/Wnt signaling in F. nucleatum, EPEC, and B.
fragilis, pro-inflammatory signaling in S. gallolyticus, and
genotoxicity in EPEC may be involved in the develop-
ment of CRC [9]. Also, specific gut bacteria might be
related to a specific molecular carcinogenesis pathway in
the colorectal. In this respect, the association between
the high concentration of F. nucleatum and mutation in
BRAF and KRAS genes has been reported [13, 14].
Recent studies have examined the association of
different bacteria with different cancers such as CRC;
however, the reports are different [15]. The association
of bacteria with CRC has been widely investigated in
Europe and North America where the genetic and ethnic
traits of patients differ from those in Asia, and this could
influence the gut microbial composition [16].
The association between multiple bacteria and CRC
has not been investigated in Iran. Hence, the current
research employs TaqMan quantitative Real-Time
Polymerase Chain Reaction (qPCR) to detect the presence
and abundance of four highly CRC-associated bacteria
(F. nucleatum, B. fragilis, EPEC, and S. gallolyticus) in
CRC and adjacent nontumor tissues. It also investigates
the association between these infectious agents and the
molecular and clinicopathologic features of CRC.
Materials and methods
Sample preparation
In the present cross-sectional study, colorectal adenocar-
cinoma and adjacent normal tissues were randomly ob-
tained from the patients who had visited the Hazrat-e
Rasool General Hospital and Imam Khomeini hospital in
Tehran between February 2019 and January 2021. The
study protocols were approved by the Ethics Committee
of the Iran University of Medical Sciences. All biopsies
were collected following resection of the primary tumor
or prior to any treatment regime. Participants were en-
rolled in the research before the surgery, and informed
consent was obtained from all patients. After arterial
ligation and surgical resection of the tissues, the samples
were quickly transferred from the operating suite to the
pathology unit where they were assessed by the patholo-
gist who was blind to the clinical and molecular infor-
mation. In addition, one part of the control mucosa
samples and one of the tumorous tissues were chosen
and fixed in RNAlater Reagent (QIAGEN, Hilden,
Germany). They were then snap-frozen and stored at −
70 °C until DNA extraction. All clinical data and required
information such as gender, age, and histopathological
parameters were captured from patients’ records and case
report forms. Of note, the exclusion criteria included
patients who had (a) colorectal tumors other than adeno-
carcinoma, (b) antibiotics, probiotics, radiotherapy, or
chemotherapy before surgery, and (c) comorbid malignan-
cies from other organs (Fig. 1) [17].
DNA extraction
Genomic DNA was extracted directly from the CRC and
adjacent normal mucosal tissues (25 mg of each tissue)
using QIAamp DNA Mini Kit (QIAGEN, Hilden,
Germany). Upon extraction, DNA quantity and quality
were analyzed at OD (260) and on an agarose gel. Then,
verified DNA extracts were preserved at − 20 °C for
subsequent analyses and qPCR.
Real-time PCR
Custom TaqMan primer-probe sets were designed to de-
tect the 16S rDNA gene sequence of B. fragilis and F.
nucleatum. Furthermore, the primer-probe set for EPEC
and S. gallolyticus was designed to target eaeA and sodA
genes of these bacteria, respectively (Table 1). The refer-
ence gene, SLCO2A1, was used for normalization of the
cycle threshold (CT) values of each bacterium, as a pre-
vious study [19]. Noteworthy, PCR assay for the detec-
tion of B. fragilis enterotoxin gene (bft) is carried out as
explained by Kouhsari et al. [20]. In this regard, B. fragi-
lis ATCC 43858 and ATCC 25285 strains were used as
positive and negative controls, respectively.
The specificities of the primers and probes were tested
by Allele ID software (v.7.5) and the EMBL-EPI and
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Fig. 1 A schematic diagram of the experimental design from the biopsy collection to statistical analyses
Table 1 Utilized primers and TaqMan probes in the present research
Target bacteria Primer/Probe Oligonucleotide sequence (50e30) Size (bp) Product size (bp) Ref
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NCBI BLAST databases. Note that in CRC cases with
detectable bacteria, the CT values in the qPCR for each
bacterium and SLCO2A1 decreased linearly in propor-
tion to the amount of input DNA (in a log scale) of the
same specimen (r2 > 0.99). Besides, all assays were car-
ried out in duplicate in a single patch and the results
were averaged, and thus the reported data in this article
are the mean values of duplicate qPCR analyses. Each
reaction mixture contained 0.5 μM of each primer,
0.25 μM of the probe, 20 ng of extracted DNA, and 9 μl
of Universal Probe Ex Taq PCR Master Mix (Ampliqon,
Denmark), in a total volume of 20 μl. Furthermore,
qPCR was conducted by Rotor-Gene 6000 real-time
PCR cycler (Qiagen Corbett, Hilden, Germany) using the
following thermocycling program: an initial holding at
95 °C for 15 min, followed by 40 cycles of denaturation
at 95 °C for 15 s, and annealing/extension at 62 °C for 30
s. All the components of the reaction mixture without
genomic DNA were used as a negative control in all ana-
lyses. The prevalence of four bacteria in every sample
was assessed as a relative unitless value normalized to
SLCO2A1 using the 2-ΔCT method (where ΔCT is the
difference in the average CT value of each bacterium
and the reference gene), as described previously [17, 19].
Finally, bacterial standard strains used in the present
investigation were F. nucleatum ATCC 25586, B. fragilis
ATCC 43858, S. bovis subsp. gallolyticus IBRC-M 10637,
and Escherichia coli EPEC (M) O55: K 59 PTCC 1269.
Pyrosequencing
Pyrosequencing of BRAF (codon 600), exon 3 of KRAS
(codons 12 and 13), and PIK3CA (exon 9) was performed
using the PyroMark Q96 ID QIAGEN software 2.5 system
according to the manufacturer’s manual. For pyrosequenc-
ing, we used specific primers one of which was biotinylated
to immobilize with streptavidin beads (GE healthcare) and
to amplify each target region. The pyrosequencing reaction
applied to Roche PCR 480 contained 20 ng of genomic
DNA and results were analyzed by PyroMark Q24 Applica-
tion Software 2.0 (v.2.0.6, Qiagen, Hilden, Germany).
Finally, the results were double-checked by a High-
Resolution Melting (HRM) analysis [21].
Statistical analyses
To test the relative quantities of each bacterium between
paired tumor and adjacent normal mucosa, we per-
formed a Wilcoxon signed-rank test and applied it to a
subset of specimens. Also, to evaluate the relationship
between the ordinal (positive or negative) categories of
the number of bacteria and categorical data, a Fisher
exact test was employed. Statistical analyses were per-
formed using GraphPad Prism v.8.3.0 and SPSS v.20.0
software (SPSS Inc. Chicago, IL, USA). A two-tailed p-value
below 0.05 was considered statistically significant.
Results
Clinicopathological features of CRC patients in Iran
The histopathologic and demographic properties of pa-
tients are shown in Table 2. Briefly, a total of 20 men
and 10 women with an average age of 57 (SD ± 11.04,
range 26–76) were included in the present study. 73.3%
of patients were struggling with grade-II (moderately dif-
ferentiated) cancer, and 13.3, 6.3, and 3.3% of them
Table 2 Clinicopathological features of the patients in the
present study (2019–2021, Number = 30)
Clinicopathological Characteristics of CRC Patients
Male/Female (n (%)) 20 (66.7%)/10 (33.3%)
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respectively with grade I (well-differentiated), grade III
(poorly differentiated), and grade IV (undifferentiated).
Noteworthy, there was only one patient (3.3%) with
Grade-X cancer (Table 2). The cohort consisted of 60%
colon and 40% rectal cancers, with proximal cancers
accounting for 30% of the colon cancers. Finally, only
3% of the patients were alcohol drinkers, while 23.3% of
them were smokers.
Bacterial quantification
We considered high linearity (r2 > 0.99) and reproduci-
bility (interassay coefficient of variation ≤1%) for valid-
ation of the qPCR assessment for each bacterium in
CRC tissue specimens (Fig. 2). 30 CRC tissues and their
adjacent normal mucosa were assessed for F. nucleatum,
and seven CRC (23%) and four non-CRC (13%) tissues
were found positive for bacterial DNA. In other words,
in four samples, F. nucleatum was identified in both the
lesion and matched normal mucosa. Moreover, the ana-
lysis of the relative abundance of F. nucleatum in CRC
tissues was conducted in a paired way by the adjacent
normal mucosa of each sample as its specific calibrator.
Findings were consistent with the unpaired analysis
results, which showed a larger quantity of F. nucleatum
in CRC tissues (40–104-fold, p < 0.01, Wilcoxon signed-
rank test) (Fig. 3). None of these patients had a history
of cancer in their family, and all were over 50 years old.
Besides, one CRC sample had a higher concentration of
bacteria compared to the matched normal mucosa (104-
fold). This sample belonged to a patient who had the
largest lesion size (9 cm) among all studied patients.
Furthermore, peritoneal seeding was observed only in
this patient.
Among four bacteria, B. fragilis had the highest
frequency and was detected in 20 (66%) CRC and 18
(60%) adjacent nontumor tissues. Noteworthy, unlike F.
nucleatum, the median abundance of B. fragilis deter-
mined by 2-ΔΔCT was significantly greater in five normal
samples than in the adjacent tumor tissues (4–100-fold).
Besides, in three samples, an equal quantity of B. fragilis
was observed in both tumor and control samples. How-
ever, statistical analyses showed that the concentration
of this bacterium was significantly higher in CRC tissues
than in control samples (12–1024-fold, p < 0.05,
Fig. 2 Quantitative Real-time Polymerase Chain Reaction (qPCR) assays for bacteria and the human reference gene (SLCO2A1) were carried out
using 10-fold dilution series from the same DNA samples. Findings were conducted with triplicate runs in three separate examinations, and
symbols showed mean, error bars, and standard deviation of cycle threshold values of triplicate runs. The coefficient of determination (r2) in the
assays for each bacterium and SLCO2A1 is shown
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Fig. 3 Relative quantification of the bacteria in CRC and adjacent normal mucous tissues. Scatter plots with bar (left) and relative amount of each
bacterium in tumor and matched adjacent normal samples (right) are illustrated. The relative quantity of F. nucleatum (n = 30, p < 0.01**) and B.
fragilis (n = 30, p < 0.05*) was significantly higher in CRC tissues than the adjacent normal mucosa that was collected 10–15 cm beyond cancer
margins. On the other hand, there was no significant difference in the relative quantification of EPEC and S. gallolyticus (n = 30, p > 0.05) between
CRC and non-CRC tissues
Shariati et al. Infectious Agents and Cancer           (2021) 16:41 Page 6 of 10
Wilcoxon signed-rank test). In addition, stage-IV cancer
and a tumor of 8 cm in size were recognized in one sam-
ple containing a high concentration of B. fragilis in CRC
tissue, compared to the paired normal mucosa (1024-
fold). Furthermore, out of the 20 tumor tissues and 18
adjacent normal samples that were positive for B. fragi-
lis, respectively 5 (25%) and 3 (16%) turned out to har-
bor the bft gene (Enterotoxigenic B. fragilis, ETBF). In
this manner, 15% of the B. fragilis-positive patients were
infected with ETBF in both adenocarcinoma and
matched adjacent normal samples, while in two patients
ETBF was just detected in tumor tissue. DNA sequen-
cing also confirmed these findings, and statistical
analyses did not show significant differences for ETBF
relative abundance between tumors and normal samples
(p > 0.05).
Moreover, S. gallolyticus was detected in three (10%)
and one (3%) paired tumor and normal samples, respect-
ively. We identified EPEC via the Intimin gene (eaeA) in
four (13%) colorectal adenocarcinomas and one (3%)
corresponding normal mucus. Interestingly, no variation
was detected for S. gallolyticus and EPEC between tumor
tissues and normal mucosa samples of CRC patients
(p > 0.05). Notably, our results did not show any signifi-
cant clinical associations between S. gallolyticus and
EPEC colonization. This is not surprising given the small
number of S. gallolyticus- and EPEC-positive patients.
Altogether, no bacteria were detected in 43.3% of the
CRC samples, while more than one bacterial species was
identified in 23.3% of the CRC biopsies.
Clinicopathological and molecular characteristics of CRC
patients and their bacterial status
In this study, no considerable correlation between the
four surveyed bacteria and CRC clinicopathological
variables such as tumor stage and location, pathological
differentiation, and infiltration depth was observed (p >
0.05). Notably, the concentration of F. nucleatum was
higher in the rectum than in the colon. Furthermore,
pathologic data about all B. fragilis-positive patients
revealed lymphovascular invasion; however, statistical
analyses did not show any correlation (p > 0.05) between
the bacterium and the mentioned markers.
We also studied CRC-related mutation. KRAS (codons
12 and 13) mutations were identified in 30% of cases,
while 60 and 30% of these cases experienced mutations
in codons 12 and 13, respectively. Besides, the most
commonly detected mutation in codon 12 was
Gly12Asp, followed by Gly12Val and Gly12Ser. More-
over, the F. nucleatum-positive CRC patients had KRAS
mutations more frequently than F. nucleatum-negative
CRC patients (p-value = 0.02) (Table 3). In contrast, we
did not find any PIK3A mutation in the samples, and
BRAF mutation was detected in only 2 (6.6%) specimens.
Finally, there was no significant correlation between
these mutations and bacterial colonization.
Discussion
In this study, the abundance of different bacteria was an-
alyzed in fresh frozen biopsies of colorectal lesions of 30
CRC patients, and the quantities were compared to their
adjacent non-CRC tissue. Furthermore, we studied the
association between the bacteria and the corresponding
clinicopathological and molecular characteristics. In
previous research, healthy controls without colorectal
neoplasia were employed as a control sample [22];
however, here, adjacent normal mucosal samples of CRC
patients were used, as it is a common approach to at-
tenuate the effect of genetic background [23]. Moreover,
different pieces of research have used Formalin-Fixed
Paraffin-Embedded (FFPE) tissue and fecal samples
instead of fresh frozen biopsies to investigate the associ-
ation between bacterial pathogens and CRC [19, 22].
Nevertheless, we analyzed fresh frozen tissues. FFPE,
due to the formation of crosslinks, interferes with the
analysis of biomolecules, especially nucleic acids [24]. In
addition, stool specimens can only partially exhibit the
mucosal bacterial composition in patients with CRC,
and Gevers et al. reported that the microbiome diversity,
such as Fusobacterium spp., could only be detected in
the tissue specimens rather than in stool samples col-
lected during diagnostic processes [2, 25]. Therefore, in
the current research, the TaqMan qPCR assay was
employed to measure the fold-change of bacteria in CRC
tissue and adjacent normal mucosal samples.
According to our findings, F. nucleatum was highly
abundant in 23% of CRC tissues compared to adjacent
normal mucosa. F. nucleatum employs different viru-
lence factors such as FadA and Fap2 to reinforce its
binding to E-cadherin, and consequently to activate the
Table 3 Correlation between bacterial population,
clinicopathological parameters, and molecular features
Spearman’s rho F. nucleatum B. fragilis S. gallolyticus EPEC
Age 0.18 0.21 0.31 0.33
Sex 0.09 0.12 0.25 0.54
Tumor location 0.06 0.25 0.48 0.51
Tumor size 0.07 0.13 0.25 0.31
Disease stage
Tumor infiltration 0.19 0.25 0.30 0.52
Lymphatic metastasis 0.11 0.08 0.29 0.46
TNM staging 0.11 0.25 0.31 0.41
KRAS mutation 0.02* 0.19 0.54 0.25
BRAF mutation 0.10 0.30 0.91 0.86
PIK3CA mutation 0.12 0.48 0.88 0.91
(*P value < 0.05. EPEC Enteropathogenic E. coli)
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B-catenin pathway and instigate an immune-mediated
inflammation. Hence, this bacterium induces an inflam-
matory and oncogenic response that may lead to the ini-
tiation and progression of CRC [8, 26]. Consistently,
various research studies have reported a positive correl-
ation between F. nucleatum and this cancer. However, F.
nucleatum abundance in patients with CRC varied be-
tween 13 and 87% in different countries [15, 19, 22, 27].
Given that the gut microbiome can differ from person to
person, some factors such as weight, body mass index,
diet, and geographical location may play an active role in
bringing about this variation. Besides, using different
detection techniques such as various real-time methods,
pyrosequencing, Fluorescence In Situ Hybridization
(FISH), and detection-specific antibodies, as well as
application of diverse samples like FFPE, fresh frozen tis-
sues, and stools can be effective in the inconsistency of
reports [15, 23]. In Iran, investigations to determine the
role of F. nucleatum in CRC are missing. Unlike our ob-
servations, Kashani et al. reported that 68% (24/35) and
24% (11/45) of Iranian CRC and non-CRC patients were
colonized by F. nucleatum, respectively [28]. A higher
degree of observed F. nucleatum colonization in CRC
patients in this study compared to ours might be due to
technical differences between simple PCR and qPCR.
Another quantification report in Iran with SYBR qPCR
assay and on stool samples reported a greater prevalence
of F. nucleatum in the tubular adenoma and villous/
tubulovillous polyp, than normal samples [29]. There-
fore, as long as false positives or negatives may be
reported in different research studies, it is strongly
recommended that standard methods be used to detect
the prevalence of F. nucleatum.
Here, we also detected B. fragilis in 66 and 60% of
CRC and nontumor tissues, respectively, and statistical
analyses showed a significantly higher prevalence rate of
this bacterium in CRC tissues (p < 0.05). Furthermore,
15% of the B. fragilis-positive patients were infected with
ETBF in both adenocarcinoma and matched adjacent
normal samples. This finding is in agreement with other
reports in Iran on mucosal biopsy samples, which
reported B. fragilis in 63% (43/68) and 81% (42/52) of
CRC patients and healthy controls, respectively [11].
Furthermore, the authors detected the bft gene in 47% of
patients and 3.8% of the healthy control samples and
showed that the level of B. fragilis and the difference be-
tween the positivity of the bft gene in CRC patients and
healthy control was statistically significant. A recent in-
vestigation in Iran identified B. fragilis in 58.3 and 26.6%
of the CRC patients and healthy volunteer stool samples.
The bft gene was also detected in 31.6% of CRC cases,
compared with only 8.3% in healthy controls [30]. Fur-
thermore, Viljoen et al. detected ETBF in 26% (14/54) of
colorectal adenocarcinomas and 28% (15/53) of adjacent
normal mucosa samples in South Africa [9]. Another
study also reported a higher number of ETBF in the
stool of Iranian patients with tubular adenoma and vil-
lous/tubulovillous polyp in contrast to the normal con-
trols [29]. It is assumed that enzymatically-active protein
toxins such as BFT and F. nucleatum Adhesin A (FadA)
can either directly induce host cell DNA damage or
interfere with essential host cell signaling pathways in-
volved in inflammation, cell proliferation, and apoptosis.
In general, different bacteria with their protein virulence
factors can affect host cell integrity, induce mutations
and genome instability, and manipulate host cell signal-
ing pathways. These effects can modulate cell prolifera-
tion, replication, and death, and coincidentally cause
transformation and cellular malignancies. In this regard,
evaluating the presence of bacterial toxins with onco-
genic potential at the transcriptional or proteomic level
will provide an additional layer of information to unravel
complex host-pathogen interactions with relevance to
CRC in the future [9, 31].
Collectively, the high frequency of B. fragilis in CRC
and adjacent normal samples illustrates the fact that
changes in bacterial composition might be linked to the
transformation of colorectal mucosa from early
adenomatous polyp stages to the latest CRC stages. By
contrast, changes in the gut microbiota could be the
consequence of CRC [16]. Nonetheless, these hypotheses
require further research to verify the possible association
between CRC and the high concentration of bacteria. As
mentioned, ETBF is found in a higher amount in sam-
ples of CRC patients than of healthy individuals. On the
other hand, based on our results and recent investiga-
tions, B. fragilis without toxin gene is also present in
tumor tissues and the exact role of this bacterial species
in the development and progression of CRS needs to be
investigated.
We also indicated that S. gallolyticus and EPEC, com-
pared to the adjacent normal mucosa, were not signifi-
cantly prevalent in CRC tissues of Iranian patients.
These results were in line with the research performed
by Viljoen et al. who did not detect S. gallolyticus in any
of the CRC or matched normal mucosa specimens [9].
They also reported a low number (6/54, 11%) of EPEC-
positive patients in their cohort. In addition, in another
research in Spain, only six out of 190 (3.2%) CRC
patients were detected by qPCR to be positive for S. gal-
lolyticus [32]. On the other hand, a recent investigation
in Iran has detected this bacterium in 40% (9/22) and
5% (2/40) of stool cases in CRC patients and healthy
controls. This study employed simple PCR and nonspe-
cific primers as markers [10]. In another examination in
China, no significant abundance of EPEC in CRC tissue
and adjacent normal mucous biopsies was identified
[16]. Therefore, inconsistent reports could originate
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from ethnic differences in susceptibility to bacterial
colonization as well as employment of varied techniques.
Recent studies have reported that the interactions
between genetic and epigenetic factors are involved in
the tumorigenesis of the bacteria such as F. nucleatum.
Accordingly, our findings revealed that there was a sig-
nificant correlation between F. nucleatum and KRAS
mutation. This result was consistent with a recent
cohort study that reported a correlation between the
abundance of this bacterium with KRAS mutation, in
Japanese CRC patients [14]. Nevertheless, previous
research did not find such a correlation [19, 27]. A rela-
tionship between the high concentration of F. nucleatum
and BRAF V600E mutation was also reported, while
such an association was not reported for KRAS [13].
This discrepancy could result from the different
methods used for evaluating the number of bacteria and
different cutoff values [14]. Furthermore, since we
included only a small number of CRC patients with
mutant genes (n = 11), more investigations would be re-
quired to analyze these correlations.
This study was subject to a number of limitations and
constraints. First, the sample size used in this investigation
was quite small. Second, due to the limited scope of
sufficient data on the follow-up, we could not assess the
bacteria for a longer period to relapse. In the end, we could
not analyze the bacterial concentration/number in the nor-
mal colorectal tissue of healthy subjects because we did not
use healthy volunteers for biopsy due to ethical issues.
Conclusion
Our analyses showed a significantly higher abundance of
F. nucleatum and B. fragilis bacteria in CRC samples
compared to normal tissues; however, we could not
detect such a relation for S. gallolyticus and EPEC. Due
to diverse reports by different research groups, it is recom-
mended that the role of each CRC-associated bacteria
with CRC be further investigated in vivo and in vitro. In-
depth research may facilitate organizing novel approaches
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